



ImmunOs Therapeutics AG partners with Locust Walk to Support Business Development Activities for their Novel Innate and Adaptive Immunotherapy Platform for Cancer

Schlieren (Zurich Area), Switzerland. – October 25, 2017 – ImmunOs Therapeutics AG, a Swiss biotechnology company leading the next generation of innate and adaptive immunity focused immunotherapies for cancer, today announced a partnership with Locust Walk to lead and support a formal business development process for their novel immuno-oncology platform.

ImmunOs Therapeutics AG CEO, Sean R. Smith commented, “Our company is receiving substantial interest and has had an on-going dialogue with leading immuno-oncology companies, corporate, and life science venture funds. We decided to partner with Locust Walk, a leading global life sciences transaction advisory firm focused on biopharmaceuticals and medical technology, to formalize a strategic partnering process, identify the best partners to accelerate development of our novel platform and bring our medicines to patients. Locust Walk has a strong track-record of success and experience in securing meaningful transactions for companies with similar stage therapeutics. ImmunOs Therapeutics intends to become a leader in the Immuno-Oncology field and is committed to a global business development campaign with Locust Walk.”

“After years of research, this is an exciting step forward as we discuss and select the best biopharma companies and institutional investors to accelerate development of our novel platform. With the announcement of our partnership with Locust Walk, our company is taking another step forward in providing novel agents to cancer patients with the greatest unmet need.” said Dr. Osiris Marroquin-Belaunzaran, Chief Scientific Officer at ImmunOs Therapeutics AG

“Our mission at Locust Walk is to help grow life science companies through transformative transactions. As part of that mission, we look forward to helping build ImmunOs into a leading Immuno-Oncology company,” said Geoff Meyerson, Managing Partner & Co-Founder.

About ImmunOs Therapeutics AG:

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing the next generation of novel human immunomodulatory proteins focused in innate and adaptive immunity. Our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.

ImmunOs Therapeutics AG lead program is a next generation, novel platform of targets that differ from the common competitor antibodies as they target diverse immunoregulatory receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (Macrophages and NK Cells) and Indirectly on the Adaptive Immune System by targeting MDSCs

and thus allowing the expansion of T cells leading to a strong anti-tumor response in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications. For more information, please visit www.immunotherapeutics.com.

About Locust Walk:

Locust Walk is an advisory firm focused on building life science companies through transformative transactions. Its team of experienced professionals fuels the growth of promising companies at every stage by connecting the right products, the right partners and the most attractive sources of capital. Locust Walk was founded in 2008 and has more than 30 full-time team members working in our offices across the world in Boston; San Francisco; Tokyo, Japan and Cologne, Germany. For further information, please visit www.locustwalk.com.



Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area)

info@immunotherapeutics.com